Cargando…

Editorial: New therapeutic approaches for SARS-CoV-2/COVID-19

Detalles Bibliográficos
Autores principales:	Rodriguez-Morales, Alfonso J., Barbosa, Alexandre Naime, Cimerman, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484607/ https://www.ncbi.nlm.nih.gov/pubmed/37691938 http://dx.doi.org/10.3389/fimmu.2023.1276279

Ejemplares similares

Human monkeypox preparedness in Latin America – Are we ready for the next viral zoonotic disease outbreak after COVID-19?
por: Cimerman, Sergio, et al.
Publicado: (2022)

Editorial: SARS-CoV-2 variants, B lymphocytes, and autoreactivity
por: Radic, Marko Z., et al.
Publicado: (2023)

Cannabidiol and SARS-CoV-2 Infection
por: Vallée, Alexandre
Publicado: (2022)

Editorial: Mucosal immunity to HIV and SARS-CoV-2 infection and vaccination
por: Bomsel, Morgane, et al.
Publicado: (2023)

Editorial: Immune response to SARS-CoV-2 and implications for clinical outcome
por: Bölke, Edwin, et al.
Publicado: (2023)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Editorial: Innate immune responses to SARS-CoV-2 in infected and vaccinated individuals
por: Saksena, Nitin K., et al.
Publicado: (2023)

Editorial: Host-microbe interaction in SARS-CoV-2 infection: mechanism and intervention
por: Kombe Kombe, Arnaud John, et al.
Publicado: (2023)

Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
por: Abdelrahman, Zeinab, et al.
Publicado: (2020)

Puerarin: A Potential Therapeutic for SARS-CoV-2 and Hantavirus Co-Infection
por: Liang, Weizheng, et al.
Publicado: (2022)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

Editorial: Cell cycle control as a new therapeutic approach for SARS-CoV-2 infection
por: Rizzo, Roberta, et al.
Publicado: (2023)

SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants
por: Martínez-Flores, Daniel, et al.
Publicado: (2021)

Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
por: Xiao, Xia, et al.
Publicado: (2020)

Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications
por: Di Vito, Clara, et al.
Publicado: (2022)

Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection
por: Liang, Yanwen, et al.
Publicado: (2020)

Comprehensive Comparison of RNA-Seq Data of SARS-CoV-2, SARS-CoV and MERS-CoV Infections: Alternative Entry Routes and Innate Immune Responses
por: Cao, Yingying, et al.
Publicado: (2021)

Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
por: Barbosa, Alexandre Naime, et al.
Publicado: (2023)

SARS-CoV-2’s Variants of Concern: A Brief Characterization
por: Scovino, Aline Miranda, et al.
Publicado: (2022)

Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
por: Chao, Chiao-Hsuan, et al.
Publicado: (2022)

Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2
por: Zhu, Ling, et al.
Publicado: (2020)

Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues
por: Subbarayan, Karthikeyan, et al.
Publicado: (2021)

SARS-CoV-2 Infection Triggers Phosphorylation: Potential Target for Anti-COVID-19 Therapeutics
por: Chatterjee, Bhaswati, et al.
Publicado: (2022)

Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
por: Santos, Susana, et al.
Publicado: (2022)

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
por: Mooij, Petra, et al.
Publicado: (2022)

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19
por: Sharun, Khan, et al.
Publicado: (2020)

Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees
por: Garziano, Micaela, et al.
Publicado: (2022)

The SARS-CoV-2 Pandemic in Latin America: the Need for Multidisciplinary Approaches
por: Callejas, Diana, et al.
Publicado: (2020)

Immunomodulatory Drugs in the Management of SARS-CoV-2
por: Burrage, Daniel R., et al.
Publicado: (2020)

Immunity to SARS-CoV-2: Lessons Learned
por: Fergie, Jaime, et al.
Publicado: (2021)

CAR Macrophages for SARS-CoV-2 Immunotherapy
por: Fu, Wenyan, et al.
Publicado: (2021)

The Spike of SARS-CoV-2: Uniqueness and Applications
por: Kumavath, Ranjith, et al.
Publicado: (2021)

SARS-CoV-2 and the host-immune response
por: Maison, David P., et al.
Publicado: (2023)

Diversity of immune responses in children highly exposed to SARS-CoV-2
por: Úbeda, María, et al.
Publicado: (2023)

Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines
por: Vitte, Joana, et al.
Publicado: (2020)

The Dynamic Role of FOXP3(+) Tregs and Their Potential Therapeutic Applications During SARS-CoV-2 Infection
por: Xu, Zhan, et al.
Publicado: (2022)

Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry
por: Palacios-Rápalo, Selvin Noé, et al.
Publicado: (2021)

HBD-2 variants and SARS-CoV-2: New insights into inter-individual susceptibility
por: Behairy, Mohammed Y., et al.
Publicado: (2022)

Neutralizing SARS-CoV-2
por: Poeschla, Eric
Publicado: (2020)

Taking on SARS-CoV-2
por: Kučan Brlić, Paola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tml7nnavat5h7bb4tiq1dv0vrs